Drugs / GEM3PSCA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03927573 | Apr 2019 → Jun 2023 | kidney cancer, non-small cell lung carcinoma, prostate cancer, transitional cell carcinoma | AvenCell Europe GmbH | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEM3PSCA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03927573 ↗ |
| Route | Intravenous | “administered intravenously” NCT03927573 ↗ |
| Target | PSCA | “a PSCA targeted bispecific antibody engaging T-cells” NCT03927573 ↗ |